Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for interleukin 23 (compound)
Most Correlated Studies
- Th1 or Th2 in the presence or absence of TGFbeta
- CD3 and CD28 Stimulated PBMCs treated with IL-23
- CD4+ T cells differentiated with alternate combinations of IL-1beta, IL-6 and TGFbeta
- L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
- L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
Most Relevant Literature
- IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.
- IL-23 to see: Gut DCs shine bright in inductive sites.
- Gums make IL-23, no professionals needed.
- Epithelial-derived interleukin-23 promotes oral mucosal immunopathology.
- IL-23 stabilizes an effector Treg cell program in the tumor microenvironment.
Most Relevant Clinical Trials
- Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy
- The Effect of Acupuncture on the Treatment of Endovenous Ablation on Pain, IL17 and IL 23
- Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
- The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of I…
- Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
